Page 23 - Replimune Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating patients whose cancer has metastasized to the liver Announces plans to initiate broad Phase 2 development of RP2 and/or RP3 in tumor types that commonly metastasize to the liver Virtual investor event to be held at 8:00 a

Published: May 13, 2021 By Alex Keown Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinic...

Oxford Properties Group is perpetuating the Bay Area and Boston-area life sciences boom with a move worth more than a quarter of a billion dollars, and it plans to use another half-billion on further capital investments. The Toronto-based investment company and developer paid $276M for four life sciences assets and plots of land suitable for development in the thriving life sciences sector, according to a press release. The deal comprises a mixed-use property in the East Bay city of Emeryville that also includes two land parcels earmarked for life sciences development, as well as three pr...

Director of Replimune Group, Inc. (NASDAQ:REPL), Rhodes Jason P, sells 67,890 shares worth $3,120,459 According to Replimune Group, Inc.'s most recent Statement Of Changes In Beneficial Ownership - Form 4 filing with the SEC dated Dec 09 07:54 PM, company Director, Rhodes Jason P disclosed selling 67,890 shares at a cost of $45.96. At the time of this transaction (Dec 07), this trade was worth $3,120,459 in total. As of Dec 07, Rhodes Jason P now owns 35,709 shares in total worth about $1,554,769.8599999999. For the last few recent trades made by Replimune Group, Inc. (NASDAQ:REPL) Director,...